PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced at the OneMedForum in San Francisco that patient dosing has begun in the Gynecologic Oncology Group (GOG) 67 patient Phase 2 study evaluating Advaxis’ ADXS-HPV construct for the treatment of advanced cervical cancer. The study is sponsored by the GOG with the majority of funding from the National Cancer Institute.
